SNORD114-25: A Potential Drug Target and Biomarker (G767605)

Target Name: SNORD114-25

NCBI ID: G767605

SNORD114-25

Other Name(s): small nucleolar RNA, C/D box 114-25 | 14q(II-25) | Small nucleolar RNA, C/D box 114-25

SNORD114-25: A Potential Drug Target and Biomarker

Small nucleolar RNA (snRNA) is a class of non-coding RNAs that play a critical role in various cellular processes, including DNA replication, gene expression, and chromatin regulation. One of the most well-studied snRNAs is SNORD114-25, which is located within the C/D box region of DNA on chromosome 17.

The C/D box is a region of DNA that is characterized by a specific sequence of base pairs. This region is involved in the regulation of gene expression and is known to play a role in the development and progression of various diseases, including cancer. The discovery of SNORD114-25 as a potential drug target and biomarker has significant implications for the treatment of these diseases.

SNORD114-25 is a non-coding RNA molecule that contains 25 amino acid residues. It is located within the C/D box region of DNA on chromosome 17 and is predicted to interact with the protein encoded by the gene snORD114. The snORD114 gene is located on chromosome 17, specifically on the X chromosome.

The C/D box region of DNA that is associated with SNORD114-25 is a stretch of DNA that contains the base pairs encoding the snORD114 protein. This region is known as the ORC1A region and is located upstream of the gene encoding the snORD114 protein. The ORC1A region is a well- conserved region that is involved in the regulation of gene expression and has been implicated in the development and progression of various diseases, including cancer.

Studies have shown that the ORC1A region is a key regulator of gene expression and that it plays a role in the development and progression of cancer. The discovery of SNORD114-25 as a potential drug target and biomarker has significant implications for the treatment of these diseases.

SNORD114-25 has been shown to play a role in the regulation of gene expression and has been predicted to interact with the protein encoded by the gene snORD114. This suggests that SNORD114-25 may be a useful biomarker for the diagnosis and treatment of diseases associated with the snORD114 gene.

In addition to its potential as a drug target and biomarker, SNORD114-25 also has significant implications for the study of small nucleolar RNA (snRNA) biology. The C/D box region of DNA that is associated with SNORD114-25 is a well- conserved region that is involved in the regulation of gene expression and has been studied extensively in the context of snRNA biology. The study of SNORD114-25 and its associated C/D box region has significant implications for our understanding of the regulation of gene expression and the role of snRNAs in this process.

In conclusion, SNORD114-25 is a potential drug target and biomarker that has significant implications for the treatment of diseases associated with the snORD114 gene. The discovery of SNORD114-25 has significant implications for the study of small nucleolar RNA (snRNA) biology and the regulation of gene expression. Further research is needed to fully understand the role of SNORD114-25 and its associated C/D box region in the regulation of gene expression and the development and progression of diseases.

Protein Name: Small Nucleolar RNA, C/D Box 114-25

The "SNORD114-25 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD114-25 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets